Edoxaban for the Treatment of Pulmonary Embolism in Hospitalized COVID-19 Patients

Overview

Journal Expert Rev Clin Pharmacol

Specialty Pharmacology

Date 2021 Aug 17

PMID 34402362

Citations 2

Authors

Valerio Langella

Roberta Bottino

Antonio Asti

Giulio Maresca

Gisella Di Palma

Domenico Pomponi

Claudia Sassone

Egidio Imbalzano

Vincenzo Russo

Affiliations

Soon will be listed here.

Abstract

Purpose: We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients.

Methods: We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitted to our Institution from 20 May 2020 to 20 November 2020 with computer tomography (CT) detected PE at admission, treated with edoxaban after initial parenteral therapy. Clinical outcomes were compared between patients with and without ARDS at admission and between those with and without CT confirmed PE resolution.

Results: 50 patients were included. Mean follow-up was 42.5 ± 10 days. No baseline differences were found between patients with ARDS (30%) and those without ARDS at admission. Patients with PE resolution (84%) were younger (), had a shorter duration of fondaparinux therapy (9.9 ± 3.8 vs 15.8 ± 7.5 days; and length of hospitalization (36 ± 8 vs 46 ± 9 days: P = compared with those without PE resolution. 2 patients experienced major bleedings. At multivariate analysis the time to edoxaban switch was the only predictor of the PE resolution (HR: 0.92; 95% C.I. 0.86 to 0.99.

Conclusion: Edoxaban was an effective and safe treatment for acute PE in COVID-19 setting.

Citing Articles

Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban.

Rashid M, Muneer S, Alhamhoom Y, Islam N Biomolecules. 2022; 12(4).

PMID: 35454179 PMC: 9027065. DOI: 10.3390/biom12040590.

Clinical Outcome of Hospitalized COVID-19 Patients with History of Atrial Fibrillation.

Russo V, Silverio A, Scudiero F, DAndrea A, Attena E, Di Palma G Medicina (Kaunas). 2022; 58(3).

PMID: 35334575 PMC: 8951344. DOI: 10.3390/medicina58030399.

References

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

Corsini A, Ferri N, Proietti M, Boriani G . Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs. 2020; 80(11):1065-1083. DOI: 10.1007/s40265-020-01328-6. View

Iba T, Levy J . Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2018; 17(2):283-294. DOI: 10.1111/jth.14371. View

Konstantinides S, Meyer G, Becattini C, Bueno H, Geersing G, Harjola V . 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019; 41(4):543-603. DOI: 10.1093/eurheartj/ehz405. View

Arnold K, Xu Y, Sparkenbaugh E, Li M, Han X, Zhang X . Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure. Sci Transl Med. 2020; 12(535). PMC: 7315409. DOI: 10.1126/scitranslmed.aav8075. View

Buller H, Decousus H, Grosso M, Mercuri M, Middeldorp S, Prins M . Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15):1406-15. DOI: 10.1056/NEJMoa1306638. View

Miesbach W . Pathological Role of Angiotensin II in Severe COVID-19. TH Open. 2020; 4(2):e138-e144. PMC: 7319800. DOI: 10.1055/s-0040-1713678. View

Russo V, Proietti R, Lodigiani C, Di Micco P . Fondaparinux and bleeding risk in COVID-19: unsolved question. Thromb Res. 2021; 200:128-129. PMC: 7870442. DOI: 10.1016/j.thromres.2021.01.025. View

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X . High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020; 46(6):1089-1098. PMC: 7197634. DOI: 10.1007/s00134-020-06062-x. View

10.

Brekelmans M, Ageno W, Beenen L, Brenner B, Buller H, Chen C . Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016; 3(9):e437-45. DOI: 10.1016/S2352-3026(16)30080-1. View

11.

Russo V, Cardillo G, Viggiano G, Mangiacapra S, Cavalli A, Fontanella A . Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. J Cardiovasc Pharmacol. 2020; 76(4):369-371. DOI: 10.1097/FJC.0000000000000893. View

12.

Young B, Ong S, Kalimuddin S, Low J, Tan S, Loh J . Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020; 323(15):1488-1494. PMC: 7054855. DOI: 10.1001/jama.2020.3204. View

13.

Parasrampuria D, Truitt K . Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2015; 55(6):641-55. PMC: 4875962. DOI: 10.1007/s40262-015-0342-7. View

14.

Russo V, Bottino R, Carbone A, Rago A, Papa A, Golino P . COVID-19 and Heart: From Clinical Features to Pharmacological Implications. J Clin Med. 2020; 9(6). PMC: 7355803. DOI: 10.3390/jcm9061944. View

15.

Tang N, Li D, Wang X, Sun Z . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844-847. PMC: 7166509. DOI: 10.1111/jth.14768. View

16.

Scudiero F, Silverio A, Di Maio M, Russo V, Citro R, Personeni D . Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res. 2020; 198:34-39. PMC: 7669475. DOI: 10.1016/j.thromres.2020.11.017. View

17.

Iba T, Levy J . Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2017; 16(2):231-241. DOI: 10.1111/jth.13911. View

18.

Stein P, Yaekoub A, Matta F, Janjua M, Patel R, Goodman L . Resolution of pulmonary embolism on CT pulmonary angiography. AJR Am J Roentgenol. 2010; 194(5):1263-8. DOI: 10.2214/AJR.09.3410. View

19.

Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E, Fan E . Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307(23):2526-33. DOI: 10.1001/jama.2012.5669. View

20.

Di Micco P, Russo V, Carannante N, Imparato M, Rodolfi S, Cardillo G . Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort. J Clin Med. 2020; 9(5). PMC: 7290348. DOI: 10.3390/jcm9051371. View